BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (berotralstat) For The Prophylaxis Of Hereditary Angioedema (hae) Attacks In Adults And Pediatric Patients 12 Years
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals received approval from the Brazilian Health Regulatory Agency for ORLADEYO (berotralstat) for prophylaxis of hereditary angioedema attacks in adults and pediatric patients aged 12 and above. This marks a significant milestone for the company, expanding its global footprint in the treatment of this rare condition.
April 17, 2024 | 8:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The approval of ORLADEYO in Brazil represents a significant expansion of BioCryst Pharmaceuticals' market, potentially increasing revenue and strengthening its position in the global market for hereditary angioedema treatments.
The approval of a new drug in a significant market like Brazil directly impacts BioCryst Pharmaceuticals by potentially increasing its revenue streams and market share in the treatment of hereditary angioedema. This regulatory milestone is likely to be viewed positively by investors, potentially leading to an uptick in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100